Beatwise The Podcast

In this episode of Beatwise the Podcast, I’m joined by Carys Barton, consultant nurse and chair-elect of the British Society for Heart Failure, to unpack the updated NICE guidelines on heart failure. With nearly a million people in the UK living with heart failure, this guidance marks a major step forward - not just for specialists, but for GPs, nurses, pharmacists, and allied healthcare professionals alike.We explore how the new recommendations aim to streamline diagnosis, prioritise early intervention, and strengthen the role of multidisciplinary teams in patient care. Carys brings valuable frontline insight into what this all means for clinical practice - highlighting the growing importance of patient education, holistic treatment strategies, and how to implement innovative therapies like those for HFpEF. If you're involved in heart failure management or want to understand the future of collaborative cardiovascular care, this one’s for you.EPISODE HIGHLIGHTS:[0:00] - Welcome to Beatwise the Podcast[0:23] - Why the updated NICE heart failure guidance matters now[0:40] - Introducing Carys Barton and her role in UK heart failure leadership[1:15] - Ongoing challenges in diagnosing and managing heart failure[4:19] - What’s new in the NICE guidelines - and why it’s a big deal[5:22] - The growing role of primary care in early detection and management[6:40] - How multidisciplinary care is reshaping heart failure treatment[11:37] - Empowering patients through education and self-care[12:54] - New therapies for HFpEF and how they fit into real-world care[15:00] - Collaboration between primary care and allied health professionals[28:32] - Overcoming barriers in delivering guideline-based care[31:12] - Final reflections and calls to actionIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

In this episode of Beatwise The Podcast, I sit down with Dr. Carol Whelan, consultant cardiologist at the Royal Free Hospital and chair-elect of the British Society for Heart Failure, to delve into one of the most under-recognised yet critical aspects of heart failure management: cardiac amyloidosis. We discuss why early detection of amyloidosis is absolutely vital, how to spot red flags, and what practical steps we can take to embed amyloidosis pathways into everyday heart failure care.Whether you're a clinician, a healthcare leader, or simply passionate about improving cardiac care, this episode offers a wealth of knowledge on standardising testing, creating equitable care models, and leveraging multidisciplinary teams. We also explore the latest in treatments, emerging research, and the powerful role of national societies in driving change. Tune in for actionable insights that can transform patient outcomes in heart failure services.EPISODE HIGHLIGHTS:[00:00] - Welcome to Beatwise The Podcast and intro to today’s focus on cardiac amyloidosis[01:12] - Why amyloidosis deserves a central place in heart failure services[01:50] - Exploring current and emerging treatments for cardiac amyloidosis[04:59] - Addressing geographical disparities in access to care[07:35] - The core elements of a well-structured heart failure pathway[10:40] - Recognising the early signs and clinical red flags of amyloidosis[12:43] - Why multidisciplinary collaboration is essential in amyloidosis care[13:37] - Dr. Whelan's personal journey and recent advancements in treatment[18:49] - What the future holds for amyloidosis care and ongoing research[20:24] - The leadership role of the British Society for Heart Failure[26:50] - Final thoughts and calls to actionIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

In this episode of Beatwise The Podcast, I sit down with leading cardiologist and clinical researcher Dr. Louise Segan to explore a groundbreaking question: Can patients with heart failure actually recover heart function through targeted treatment of atrial fibrillation (AF)?We dive into the fascinating findings of the Withdraw HF study, which investigates heart failure patients with atrial fibrillation and examines whether their heart function can improve enough to reduce - or even withdraw - heart failure medication. Dr. Segan shares insights into personalized treatment strategies, the role of rhythm control in AF-mediated cardiomyopathy, and what this could mean for the future of heart failure care.Whether you're a clinician, a researcher, or someone personally impacted by AF or heart failure, this episode offers cutting-edge research and practical takeaways that could reshape how we think about heart recovery.EPISODE HIGHLIGHTS:[0:00] - Welcome to Beatwise: Introducing the episode and guest, Dr. Louise Segan[1:09] - What is atrial fibrillation and how does it relate to heart failure?[5:08] - Understanding AF-mediated cardiomyopathy and its management challenges[8:59] - Inside the Withdraw HF study: why it was launched and how it was designed[14:10] - What the results reveal about heart function recovery and medication withdrawal[23:50] - Why ongoing monitoring and individualized care are essential for long-term success[29:17] - Final thoughts on the future of personalized heart failure treatmentIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

What happens when a rare condition silently disrupts a life - and no one can figure out what’s wrong? In this powerful episode of Beatwise The Podcast, I sit down with Sam Jarrett, a courageous woman navigating the complex world of amyloidosis - a rare and often misdiagnosed disease that affects the body’s organs and tissues.Together, we explore Sam’s personal and emotional path to diagnosis after months of unexplained symptoms and frustration within the healthcare system. She opens up about her life-changing experience at the National Amyloidosis Centre in London, the hope she found through participation in a clinical trial, and what she wants others living with rare diseases to know. Whether you're a medical professional, caregiver, or someone seeking answers, this episode offers deep insight into the importance of early detection, patient advocacy, and the evolving landscape of amyloidosis treatment.EPISODE HIGHLIGHTS:[00:00] Introduction to amyloidosis and why awareness matters[01:42] The beginning of Sam’s journey: symptoms and misdiagnoses[05:11] What exactly is amyloidosis? A simplified breakdown[10:56] Inside the National Amyloidosis Centre: care that changed everything[19:34] The power of clinical trials in rare disease treatment[26:32] Living well with amyloidosis: support, care, and hope[34:40] Final thoughts and what we can all learn from Sam’s storyIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

In this episode of Beatwise the Podcast, I’m joined by Dr. Edgar Argulian, a cardiologist from Mount Sinai Morningside in New York and senior author of a compelling new study published in European Heart Journal – Imaging Methods and Practice. We dive into a fascinating and often overlooked issue in cardiology: what happens when patients present with chest pain and abnormal stress echocardiograms, but their angiograms show no major coronary blockages?This conversation sheds light on the reality of non-obstructive coronary artery disease (iNOCAD) and microvascular angina, conditions especially common in women and frequently misdiagnosed or minimized. We explore the significance of these findings, the diagnostic challenges, and why we must take these patients seriously. Dr. Argulian also shares how clinicians can better identify at-risk patients and what lifestyle and treatment strategies can truly make a difference.EPISODE HIGHLIGHTS:[0:00] Welcome to Beatwise and today’s topic[0:50] Meet Dr. Edgar Argulian and overview of the study[2:20] What is Non-Obstructive Coronary Artery Disease (iNOCAD)?[3:13] Recognizing the symptoms and diagnostic pitfalls[7:25] What the study reveals about stress echo abnormalities[10:03] Key takeaways for patients and healthcare providers[16:19] Understanding the underlying causes and treatment options[17:43] Why patient advocacy, especially for women, matters[22:24] Final thoughts and future directions in heart health researchIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

What if the real root cause of cardiovascular disease isn't just lifestyle, but poverty? In this powerful episode of Beatwise the Podcast, I sit down with Helen Rowe, author of Eliminating Poverty in Britain, to unpack how deeply interconnected poverty is with heart health and why this issue can no longer be ignored.Together, we explore the social determinants of cardiovascular disease, including how poverty fuels conditions like hypertension, diabetes, obesity, and chronic stress. Helen shares the biological toll of economic inequality, how current UK government policies are exacerbating health disparities, and what it will take to create systemic change.Whether you're a healthcare professional, policymaker, or concerned citizen, this episode challenges you to see cardiovascular health through a wider lens and to take action.EPISODE HIGHLIGHTS:[0:00] Welcome to Beatwise the Podcast[0:24] Rethinking the root causes of cardiovascular disease[0:37] The powerful link between poverty and public health[1:08] Introducing guest Helen Rowe[1:42] Helen’s background and the inspiration behind her book[3:02] The current state of poverty in Britain[5:51] Personal insights and stories from the frontlines[7:29] How poverty biologically impacts the body and heart[12:49] Examining UK government policies and systemic barriers[22:41] The NHS, prevention, and the need for holistic care[32:16] Practical solutions and hope for eliminating poverty[36:40] Final thoughts and a call to rethink public health[37:30] Outro and ways to stay connectedIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

If you've never heard of amyloidosis - or assumed it was rare and irrelevant - this episode might just change everything. I'm Dr. Sarah Birkhoelzer, and in this episode of Beatwise the Podcast, I'm joined by cardiologist Dr. Sarah Cuddy from Brigham and Women’s Hospital for an eye-opening conversation about this often-misdiagnosed and misunderstood condition.We dive deep into amyloidosis symptoms, the diagnostic journey, and how this sneaky condition can mimic or even drive other common issues like carpal tunnel, neuropathy, and heart failure. We explore the two main types - Transthyretin Amyloidosis (ATTR) and Light Chain Amyloidosis (AL) - and how they affect the heart, kidneys, and nervous system. Dr. Cuddy shares why early detection is critical, how doctors are collaborating more effectively across specialties, and the exciting breakthroughs in amyloidosis treatment, from TTR stabilizers to gene therapies.If you or someone you know is facing complex, unexplained health symptoms, this episode is a must-listen.EPISODE HIGHLIGHTS:[0:00] Welcome to Beatwise and today’s focus: understanding amyloidosis[0:48] Meet Dr. Sarah Cuddy and her mission to uncover hidden cardiac diseases[1:04] What exactly is amyloidosis - and why it often gets missed[2:38] Breaking down the types: ATTR vs AL amyloidosis explained[4:36] How amyloidosis is diagnosed - and why it’s not always straightforward[8:40] Symptoms you shouldn’t ignore: nerves, kidneys, heart, and more[14:14] Amyloidosis in the heart: signs, risks, and how it shows up in cardiology[19:16] The latest treatment options, from stabilizers to gene therapies[24:07] Dr. Cuddy’s advice for patients and providers navigating complex cases[27:11] Wrap-up and a call to think amyloidosis when symptoms don’t add upIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!

In this episode of Beatwise The Podcast, I’m joined by renowned cardiologist Dr. Muthu Vaduganathan to dive deep into one of the most exciting developments in cardiorenal medicine: Finerenone. We explore its role as a mineralocorticoid receptor antagonist and its game-changing potential in treating patients with chronic kidney disease (CKD) and type 2 diabetes - two conditions that often go hand-in-hand with heart failure.We break down key insights from landmark clinical trials, including the FINEARTS-HF trial, and how Finerenone is reshaping treatment strategies for both kidney and heart health. Dr. Vaduganathan also shares practical guidance on integrating Finerenone into clinical practice, potential side effects to consider, and why patient involvement in research is more important than ever. If you’re a clinician, researcher, or someone passionate about emerging treatments in cardiovascular care, this one’s for you.EPISODE HIGHLIGHTS:[0:00] - Welcome to Beatwise The Podcast[0:31] - Meet Dr. Muthu Vaduganathan: Leading voice in cardiovascular medicine[0:57] - What is Finerenone? Understanding this novel therapy[2:23] - How Finerenone compares to current treatment options[4:08] - Landmark kidney trials: Finerenone’s impact in CKD and T2D[7:26] - Clinical insights from the FINEARTS-HF trial and heart failure care[12:43] - Encouraging patient participation in trials and treatment decisions[17:14] - Where guidelines stand now - and where they’re headed next[21:34] - Final thoughts and key takeaways for clinicians and patients alikeIf you enjoyed this episode, please like, rate, and subscribe to Beatwise The Podcast. Your support helps me reach more listeners and continue providing valuable content.Don't forget to follow me on social media @sarah.theheartdoc for the latest updates, behind-the-scenes content, and more engaging discussions. Stay connected and be part of our growing community!